Equities research analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL) will announce $459.17 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Charles River Laboratories International’s earnings, with the lowest sales estimate coming in at $454.50 million and the highest estimate coming in at $471.00 million. Charles River Laboratories International reported sales of $425.72 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.9%. The company is expected to issue its next earnings results on Wednesday, November 1st.

On average, analysts expect that Charles River Laboratories International will report full year sales of $459.17 million for the current fiscal year, with estimates ranging from $1.83 billion to $1.87 billion. For the next year, analysts forecast that the company will report sales of $1.98 billion per share, with estimates ranging from $1.96 billion to $2.01 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.22 by $0.07. The business had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a return on equity of 27.02% and a net margin of 10.13%. The company’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same period last year, the firm earned $1.20 EPS.

A number of equities analysts recently issued reports on CRL shares. Zacks Investment Research lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Citigroup Inc. reissued a “neutral” rating and issued a $104.00 price objective (up from $91.00) on shares of Charles River Laboratories International in a report on Wednesday, June 28th. BidaskClub lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Credit Suisse Group reissued a “neutral” rating and issued a $95.00 price objective (up from $89.00) on shares of Charles River Laboratories International in a report on Tuesday, June 6th. Finally, Robert W. Baird reissued a “buy” rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a report on Friday, September 1st. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $98.55.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Charles River Laboratories International, Inc. (CRL) Will Announce Quarterly Sales of $459.17 Million” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/brokerages-expect-charles-river-laboratories-international-inc-crl-will-announce-quarterly-sales-of-459-17-million.html.

In other Charles River Laboratories International news, insider Davide Molho sold 5,982 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $107.55, for a total value of $643,364.10. Following the completion of the sale, the insider now directly owns 22,714 shares in the company, valued at $2,442,890.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the completion of the sale, the insider now owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Insiders sold 79,982 shares of company stock valued at $7,951,868 over the last 90 days. 2.20% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Davidson Kempner Capital Management LP acquired a new stake in Charles River Laboratories International in the second quarter worth approximately $10,115,000. Lord Abbett & CO. LLC acquired a new stake in Charles River Laboratories International in the second quarter worth approximately $65,915,000. WINTON GROUP Ltd acquired a new stake in Charles River Laboratories International in the second quarter worth approximately $16,008,000. Public Employees Retirement System of Ohio lifted its position in Charles River Laboratories International by 1.5% in the second quarter. Public Employees Retirement System of Ohio now owns 22,383 shares of the medical research company’s stock worth $2,264,000 after purchasing an additional 330 shares during the period. Finally, Koch Industries Inc. acquired a new stake in Charles River Laboratories International in the second quarter worth approximately $240,000. Hedge funds and other institutional investors own 95.82% of the company’s stock.

Shares of Charles River Laboratories International (CRL) opened at 106.02 on Friday. The stock has a 50 day moving average price of $103.01 and a 200 day moving average price of $95.28. Charles River Laboratories International has a 12-month low of $67.20 and a 12-month high of $109.59. The firm has a market capitalization of $5.05 billion, a PE ratio of 27.94 and a beta of 0.99.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.